Technology Park being developed to facilitate Deep-tech Start-ups: MoS (See 'Corp Brief') PMLA - ED cannot arrest accused without prior approval from Special Court once cognizance is taken, even if ECIR is filed earlier & accused cooperates throughout investigation: HC (See 'Legal Desk') Estee Lauder joins hands with DPIIT to promote women-led startups in beauty products sector (See 'Corp Brief') SARFAESI - Auction purchaser can't be fastened with outstanding liability of dues and taxes, which had accrued and were connected with and were solely attributable to business of erstwhile dealer: HC (See 'Legal Desk') Khadi artisans to receive wage hike from April 01, 2025 (See 'Corp Brief') A&C - Unless there exists error, apparent which goes to root of matter, interference by court with arbitral award is not warranted: HC (See 'Legal Desk') Govt hosts workshop on increasing R&D in pharma-medical tech sector (See 'Corp Brief') Misc - Degree of integrity & probity is expected of Chartered Accountant because of trust posed in him by his clients, and his professional misconduct erodes credibility to Institution of Chartered Accountants: HC (See 'Legal Desk') CCI okays proposed combination via acquisition of Ayana Renewable Power Pvt. Ltd. by ONGC NTPC Green Pvt. Ltd. (See 'Corp Brief') Companies Act - Findings of apex expert body like RBI warrant for issuance of protective ad-interim orders: HC (See 'Legal Desk') CCI okays acquisition of certain shareholding in Greenko Energy Holdings of ORIX Corporation (See 'Corp Brief') IPR - Manufacturer of counterfeit products, for its blatant act of counterfeiting, shall be restrained from selling products under registered brand's trademarks and its logos, and shall pay for damages: HC (See 'Legal Desk') Companies Act 2013 adequately bolsters corporate governance & ensures transparency: MoS (See 'Corp Brief') IBC - AR trying to evade to take up request of financial creditors for replacement of RP and failing to represent interest of financial creditors, violates Sec 25A: IBBI (See 'Legal Desk') Rs 25 Lakh loans, decision in 14 days - Govt moves to enhance credit access for MSMEs (See 'Corp Brief') SEBI - Passing of Settlement Order shall be without prejudice to rights of SEBI, including restoring or initiating of proceedings, if there was discrepancy while arriving at settlement terms: SEBI (See 'Legal Desk') MSME Sector sees continued growth as NPAs fall (See 'Corp Brief') SEBI - By not taking prior approval of audit committee for RPTs, Noticee has violated Regulation 23(2) of LODR Regulations: SEBI (See 'Legal Desk') Natural Products Expo West 2025 - APEDA showcases Indian prowess in organic farming (See 'Corp Brief') IPR - Sporadic use of trademark in India is no ground to assume that said trademark has acquired reputation and goodwill of mark in India: HC (See 'Legal Desk') PMLA - Mere attachment of property does not alter position with regard to ownership or even possession/use of properties which are subject matter of such attachment: SAFEMA (See 'Legal Desk') NHLML, IWAI ink MoU for state-of-art Multi-Modal Logistics Park in Varanasi (See 'Corp Brief') IBC - Prima facie contraventions of regulations, including failure to maximize stakeholder value and non-compliance with auction procedures, justifies initial suspension of registration for two years: IBBI (See 'Legal Desk') Govt announces reward for developing toys fostering learning & child development (See 'Corp Brief') Misc - Case under Negotiable Instrument Act, can't be transferred from one place to another for lack of jurisdiction u/s 406 of CrPC: SC (See 'Legal Desk') Space Technology revolutionizes governance, agriculture & Defence: MoS (See 'Corp Brief') PC Act - Anticipatory bail should only be granted in exceptional cases where there is prima facie indication of false implication or frivolous allegations: SC (See 'Legal Desk') Department of Fisheries hosts Fisheries Startup Conclave 2.0 in Hyderabad (See 'Corp Brief') PMLA - High Court can't direct ED to register ECIR only based on its prima facie finding on predicate offence: SC (See 'Legal Desk') Mandaviya joins in unique Cycle Rally to mark International Women's Day (See 'Corp Brief') Trade Marks Act 1999 - new Trade Mark identical to existing RAPIDO trade mark, warrants cancellation, as it seeks to dishonestly exploit goodwill & reputation of existing Trade Mark holder: HC (See 'Legal Desk') IBC - Section 95 application filed by Respondent No.1 Bank is valid: NCLAT (See 'Legal Desk')

Print

Govt hosts workshop on increasing R&D in pharma-medical tech sector

Published: Mar 13, 2025

By TIOLCorplaws News Service

NEW DELHI, MAR 13, 2025: THE Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, organised a workshop on the Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) Scheme today. The workshop was inaugurated in the presence of the Secretaries of five stakeholder Ministries and Departments of the Government of India, namely, Amit Agrawal, Secretary, Department of Pharmaceuticals; Prof. Abhay Karandikar, Secretary, Department of Science and Technology (DST); S. Krishnan, Secretary, Ministry of Electronics and Information Technology (MeitY); Dr N. Kalaiselvi, Secretary, Department of Scientific and Industrial Research (DSIR) and Director General (DG), Council of Scientific and Industrial Research (CSIR); and Dr Rajiv Bahl, Secretary, Department of Health Research (DHR) and DG, Indian Council for Medical Research (ICMR). The workshop served as a platform for identifying key action points and approaches to further the shared commitment to promote research and development in the pharmaceuticals and medical technologies sector.

Amit Agrawal, Secretary, Department of Pharmaceuticals highlighted the rapid expansion in the sector, underscoring the importance of research and innovation in driving making and innovating in India for India and the world. In this regard, he highlighted that the global share of personalised and precision technology platforms (such as antibody-drug conjugates, bi-specific antibodies, and cell and gene therapy) among the top-100 drugs by value is growing rapidly, from 5% in 2020 to 9% in 2025 and projected to grow to 20% by 2030. He also highlighted the 10 times increase in the number of Indian healthcare and life sciences startups over the last four years, from over 900 in 2020 to more than 10,000 in 2024, as well as the growing pipeline of innovative products of Indian firms.

Amit Agrawal said that the groundwork and the pipeline for projects for the PRIP scheme has been laid through this growing innovation ecosystem of Indian startups and industry, supported by a wide array of initiatives of the scientific Ministries/ Departments. The latter include the clinical trial network created by CSIR under its INTENT initiative; the patenting support available through DST's TIFAC and ICMR's Patent Mitra initiative; the handholding support available to both medical technology and drug innovations through ICMR's MedTech Mitra initiative; the funding support available to startups through Department of Biotechnology's BIRAC, MeitY's TIDE 2.0 and SAMRIDH schemes and DST's Quantum Computing Mission, etc.

Reiterating the Government's commitment to a robust research ecosystem, Amit said that PRIP is a transformative initiative aimed at catalysing innovation, strengthening industry-academia linkages, and positioning India as a global leader in pharmaceutical and MedTech research.

Prof. Abhay Karandikar, Secretary, DST underscored the importance of cutting-edge scientific research in driving advancements in pharmaceuticals and MedTech, reinforcing India's healthcare ecosystem and highlighted the supports available through the extensive incubator and accelerator network of DST.

S. Krishnan, Secretary, MeitY emphasised the transformative potential of digital health, artificial intelligence (AI) and data-driven technologies in drug discovery and medical device development. He highlighted the research strengths of MeitY's organisations, such as Society for Applied Microwave Electronics Engineering and Research (SAMEER), C-DAC and Centre for Materials for Electronics Technology (C-MET).

Dr Rajiv Bahl, Secretary, DHR and DG, ICMR highlighted the critical role of clinical research, indigenous drug development and regulatory advancements in accelerating pharmaceutical innovation. He offered the full support of the ICMR INTENT, MedTech Mitra and Patent Mitra initiatives in taking forward the shared goals of PRIP scheme. He also said that the industry-academia collaborative research window under the scheme could be of considerable help in taking forward the large volume of intramural and extramural research being funded by ICMR to the market with funding from PRIP and industry involvement.

Dr N. Kalaiselvi, Secretary, DSIR and DG, CSIR underscored the need to foster a culture of scientific collaboration between research institutions and industry to ensure the seamless translation of research into commercially viable applications. She highlighted that considerable research done in CSIR labs could be taken to the market through collaboration with industry and funding from PRIP.

The discussions reaffirmed the Government's vision of transforming India into a global hub for research and innovation in pharmaceuticals and medical technology. The workshop featured four dedicated breakout sessions, bringing together over 100 participants from leading scientific departments and premier institutions, including the National Institutes of Pharmaceutical Education and Research, IITs, CSIR labs and organisations of ICMR, MeitY, DST and Department of Bio technology, along with key government enablers for the ecosystem. Key deliberations covered the emerging trends in pharmaceutical and MedTech research, strategies for translating research into commercially viable products, government support mechanisms to accelerate sectoral growth and flexibilities sought to maximise the impact from the PRIP scheme.

All participants were requested to share their suggestions in the Expression of Interest (EoI) form for the PRIP scheme hosted on the website of the Department of Pharmaceuticals, so that these may be taken into account while taking forward the scheme and enabling participants. The EoI would be open till April 7, 2025.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
taxindiaonline
A Taxongo Website. Copyright © 2016-2022 tiolcorplaws.com All rights reserved.